AR and prostate cancer: Furthermore, EGCG induced chemosensitization in all stages of breast and prostate cancer, by receptor-mediated mechanisms; indeed, it antagonized androgen action and decreased androgen receptor (AR) expression in hormone-responsive prostate cancer cells [16].